CN1650864A - 10-hydroxy camptothecin long cyclic liposome and its freeze aried preparation - Google Patents
10-hydroxy camptothecin long cyclic liposome and its freeze aried preparation Download PDFInfo
- Publication number
- CN1650864A CN1650864A CN 200410084647 CN200410084647A CN1650864A CN 1650864 A CN1650864 A CN 1650864A CN 200410084647 CN200410084647 CN 200410084647 CN 200410084647 A CN200410084647 A CN 200410084647A CN 1650864 A CN1650864 A CN 1650864A
- Authority
- CN
- China
- Prior art keywords
- hydroxycamptothecine
- polyethylene glycol
- long circulating
- preparation
- liposome
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Landscapes
- Medicinal Preparation (AREA)
Abstract
A long-cycle lipoid of 10-hydroxyamptothecin and its freeze dried medicine for treating cancer are prepared from lecithin, PEG modified bipid, cholesterol, mycose or cane sugar, alcohol and dichloromethane.
Description
Technical field
The invention belongs to field of pharmaceutical preparations, relate to the 10-hydroxycamptothecine long circulating liposomes, lyophilized formulations of long circulating liposomes and preparation method thereof.
Background technology
(Hydrocamptothecin HCPT) is the strongest micro-alkaloid of antitumaous effect in the similar antitumor monomer that extracts in the 60-70 age in this century to 10-hydroxycamptothecine from Chinese Fructus seu radix camptothecae acuminatae (Fructus Camptothecae Acuminatae), be S-phase specificity cancer therapy drug.Its anticancer mechanism of the pharmacological research of system is for suppressing Topo I, clinical ascitic type liver cancer, tumor of head and neck, gastric cancer and bladder cancer and the leukemia of mainly applying to, the toxic reaction of HCPT mainly shows the inhibition of urinary system, digestive system and hemopoietic function etc., but its toxicity is starkly lower than camptothecine, particularly the urinary system reaction is few, easily is accepted clinically.At present, the subject matter that this medicine exists has: the half-life short (5min-1h), need repetitively administered, so toxic and side effects is bigger; Fat-soluble strong, and the active anticancer reduction by 90% of making the water solublity sodium salt; Poor stability, the lactonic ring of medicine are lost pharmacologically active to light, thermo-responsive after the lactonic ring open loop.At present, domesticly clinically be form (patent 02138930.6 and 02114913.5) with the salt of the open loop of HCPT with preparation, such preparation drug effect significantly descends, and toxicity increases, thereby has limited clinical practice.Research is one of main direction of its research to the 10-hydroxycamptothecine novel form at present.
The half-life of 10-hydroxycamptothecine is short, only be about 5min-1h, on the treatment characteristics, such medicine is in concentration that affects the treatment and time factor, time is principal element, belong to the time-dependent medicine, be mainly used in poky tumor treatment, so this mechanism of action requires its long-term prescription.Many studies show that, administration nano-drug administration system have good targeting and slow releasing function, are particularly conducive to the anticancer therapy of such time-dependent sexual type medicine and the fast medicine of metabolism.Employing absorption-packs such as domestic Zhang Zhi's honor have prepared the 10-hydroxycamptothecine PBCA nanoparticle of polyvinyl pyridine alkane ketone bag quilt, experimental results show that this medicine carrying nanoparticle has tangible liver targeting and slow releasing function.Domestic patent 03152834.1 discloses the Emulsion and the Emulsion of 10-hydroxycamptothecine, has increased stability of drug, has changed medicine distribution in vivo, has improved the curative effect of medicine.Domestic patent 01138252.X has prepared 10-hydroxycamptothecine glucosan nanoparticle, 01133700.1 prepared polylactic acid nano particle, 03113179.4 prepared the liposome of HCPT, these preparations show to have the higher selectivity of reticuloendothelial system (liver, spleen etc.), better to treatment hepatocarcinoma, but not in other tumors of reticuloendothelial system, such preparation does not only have targeting, has also increased the toxicity of medicine to reticuloendothelial system as if lesions position.
Summary of the invention
The object of the present invention is to provide the long circulating liposomes of 10-hydroxycamptothecine and the freeze-dried preparation of long circulating liposomes.Preparation of the present invention can disperse with normal saline or glucose injection, is used for intravenously administrable.
Characteristics of the present invention are to use the lipid of PEGization to come modified liposome, and it is bigger to solve the traditional liposomal particle diameter on the one hand, poor stability, the problem of easily leakage, fusion and lyophilization difficulty; Surface of liposome is modified by PEG, form a kind of spatial " conformation cloud ", the absorption of opsonic identification and plasma protein in the prevention blood, reduce liposome engulfing by reticuloendothelial system, thereby the removing speed of liposome is slowed down, and residence time prolongs in the blood, helps it and enters tumor tissues, and promote its infiltration and delay effect (EPR effect), thereby reach cancer target and efficacy enhancing and toxicity reducing effect to tumor tissues.
The lipid of PEGization involved in the present invention comprises the phospholipid such as the hard ester acyl PHOSPHATIDYL ETHANOLAMINE (PEG-DSPE) of Polyethylene Glycol-two of PEGization; Block or friendship graft copolymer class such as polyethylene glycol-caprolactone (PEG-PCL), polyethylene glycol-Acetic acid, hydroxy-, bimol. cyclic ester lactide (PEG-PLGA), polyethylene glycol-lactic acid (PEG-PLA), polyethylene glycol-cetyl cyanoacrylate (PEG-PHDCA) etc.; Surfactant-based as poloxamer 188 (Pluronic F68), polyoxyethylene fatty acid ester class (Mrij), polyoxyethylene fatty acid ether (Brij), polyoxyethylene hydrogenated Oleum Ricini (Cremophor) etc.Its common trait is that an end is hydrophilic Polyethylene Glycol, because PEG has hydrophilic and pliability preferably, is proved to be best face finish material at present; The other end then is lipophilic hydrophobic side, can well be embedded in the double-layer of lipoid of liposome to form lipid film jointly with phospholipid.
The present invention carries out around the preparation of 10-hydroxycamptothecine, but also can be used for other water insoluble camptothecins such as camptothecine, 9-aminocamptothecin, 9-nitrocamptothecin etc., the 10-hydroxycamptothecine of treatment cancer prepared in accordance with the present invention is compared with existing clinical dosage form, toxicity is less and more stable, and its anti-tumor activity improves greatly.
Purpose of the present invention is achieved through the following technical solutions:
The 10-hydroxycamptothecine long circulating liposome preparation is characterized in that following weight proportion medicine is a raw material: 10-hydroxycamptothecine 1-5 part, phosphatidase 11 0-100 part, lipid 10-100 part, cholesterol 2-50 part, trehalose or sucrose 10-400 part that PEG modifies.
Described phospholipid is lecithin, soybean phospholipid or hydrogenated soya phosphatide;
Described PEGization lipid is the hard ester acyl PHOSPHATIDYL ETHANOLAMINE (PEG-DSPE) of Polyethylene Glycol-two, polyethylene glycol-caprolactone (PEG-PCL), polyethylene glycol-Acetic acid, hydroxy-, bimol. cyclic ester lactide (PEG-PLGA), polyethylene glycol-lactic acid (PEG-PLA), polyethylene glycol-cetyl cyanoacrylate (PEG-PHDCA), poloxamer 188 (Pluronic F68), polyoxyethylene fatty acid ester class (Mrij), polyoxyethylene fatty acid ether (Brij), polyoxyethylene castor oil ether (Cremophor) wait one of them or any combining form.
Technical solution of the present invention also relates to the preparation method of described 10-hydroxycamptothecine long circulating liposome preparation, it is characterized in that following weight proportion medicine is a raw material: 10-hydroxycamptothecine 1-5 part, phosphatidase 11 0-100 part, cholesterol 2-50 part, trehalose or sucrose 10-400 part.The process preparation of freeze-dried preparation by may further comprise the steps: phospholipid, cholesterol and HCPT are dissolved in certain mixed organic solvents, remove organic solvent, constant temperature removes and desolvates, vacuum drying, adding is dissolved with in the trehalose or aqueous sucrose solution of aforementioned proportion, after the aquation dissolving, available ultrasound wave or high pressure dispersing emulsification machine are handled, divide in the container of packing into, lyophilization, the lyophilizing long circulating liposome preparation of 10-hydroxycamptothecine.Seal or can use nitrogen, helium, carbon dioxide or argon during gland.
Described phospholipid is lecithin, soybean phospholipid or hydrogenated soya phosphatide or wherein any two kinds of mixture.
Described PEGization lipid is the hard ester acyl PHOSPHATIDYL ETHANOLAMINE (PEG-DSPE) of Polyethylene Glycol-two, polyethylene glycol-caprolactone (PEG-PCL), polyethylene glycol-Acetic acid, hydroxy-, bimol. cyclic ester lactide (PEG-PLGA), polyethylene glycol-lactic acid (PEG-PLA), polyethylene glycol-cetyl cyanoacrylate (PEG-PHDCA), poloxamer 188 (Pluronic F68), polyoxyethylene fatty acid ester class (Mrij), polyoxyethylene fatty acid ether (Brij), polyoxyethylene hydrogenated Oleum Ricini (Cremophor) wait one of them or any combining form.
It is 40-60 ℃ that used constant temperature is removed solvent temperature.
Used organic solvent can be dichloromethane, chloroform, ethanol, methanol, oxolane, dimethyl sulfoxide and composition thereof.
Used hydration temperature can be 10-80 ℃.
Used freeze drying protectant also can be trehalose, sucrose, glucose, lactose, dextran, mannitol, F68 (poloxamer 188) and composition thereof.
Beneficial effect of the present invention shows: can stablize the Alpha-hydroxy lactonic ring of 10-hydroxycamptothecine, it is existed with closed loop, increase stability of drug; Can increase the water solublity of 10-hydroxycamptothecine, improve the suitable pin of injection; Can increase the half-life of 10-hydroxycamptothecine, increase its blood circulation time; Can improve the effect of target tumor, improve the curative effect of medicine, reduce toxicity; The lyophilized preparation of the present invention's preparation aquation again forms liposome solutions, increases stability of formulation; The present invention adopts membrane process preparation, technology simple possible.
Description of drawings
The release in vitro of the liposome that Fig. 1 .Brij-40 modifies: discharge percentage rate-time graph.
Fig. 2. the particle size distribution figure of liposome.
Fig. 3. with haemoconcentration (cpm/0.5ml) time graph of the lipid-modified liposome of various PEGization.
The specific embodiment
Embodiment 1.
With 10-hydroxycamptothecine 1g, phosphatidase 15 0g, cholesterol 15g, hard ester acyl PHOSPHATIDYL ETHANOLAMINE (PEG-DSPE) 5g of Polyethylene Glycol-two is dissolved in chloroform: in the methanol (2: 1), rotary evaporation is removed organic solvent, vacuum drying, adding is dissolved with in the trehalose and sucrose water (1: 1) solution of 100g aquation 30min, use ultrasonic Treatment, promptly get the long circulating liposomes solution of 10-HCPT.
Embodiment 2.
With 10-hydroxycamptothecine 2g, phosphatidase 15 0g, cholesterol 10g, polyethylene glycol-caprolactone (PEG-PCL) 10g is dissolved in chloroform: in the methanol (2: 1), rotary evaporation is removed organic solvent, vacuum drying, adding is dissolved with in the aqueous trehalose of 100g aquation 30min, handle with the high pressure dispersing emulsification machine, promptly get the long circulating liposomes solution of 10-HCPT.
Embodiment 3.
With 10-hydroxycamptothecine 4g, phosphatidase 15 0g, cholesterol 20g, polyethylene glycol-Acetic acid, hydroxy-, bimol. cyclic ester lactide (PEG-PLGA) 8g is dissolved in dichloromethane: in the ethanol (2: 1), rotary evaporation is removed organic solvent, vacuum drying, adding is dissolved with in the mannose and sucrose water (1: 1) solution of 70g aquation 30min, with handling, promptly get the long circulating liposomes solution of 10-HCPT with the high pressure dispersing emulsification machine.
Embodiment 4.
With 10-hydroxycamptothecine 1g, phosphatidase 15 0g, cholesterol 25g, polyethylene glycol-lactic acid (PEG-PLA) 5g is dissolved in chloroform: in the methanol (2: 1), rotary evaporation is removed organic solvent, vacuum drying, adding is dissolved with in the mannose and sucrose water (1: 1) solution of 100g aquation 30min, use ultrasonic Treatment, promptly get the long circulating liposomes solution of 10-HCPT.The liposome branch is packed in the container, lyophilization, the lyophilizing long circulating liposome preparation of 10-hydroxycamptothecine.Logical nitrogen seals.
With 10-hydroxycamptothecine 4g, phosphatidase 15 0g, cholesterol 15g, poloxamer 188 (Pluronic F68) 10g is dissolved in dichloromethane: in the ethanol (2: 1), rotary evaporation is removed organic solvent, vacuum drying, adding is dissolved with in the trehalose and sucrose water (1: 1) solution of 100g aquation 30min, use ultrasonic Treatment, promptly get the long circulating liposomes solution of 10-HCPT.The liposome branch is packed in the container, lyophilization, the lyophilizing long circulating liposome preparation of 10-hydroxycamptothecine.Logical nitrogen seals.
Embodiment 6.
With 10-hydroxycamptothecine 1g, phosphatidase 15 0g, cholesterol 15g, polyoxyethylene fatty acid ester (Mrij-100) 5g is dissolved in chloroform: in the methanol (2: 1), rotary evaporation is removed organic solvent, vacuum drying, adding is dissolved with in the trehalose and sucrose water (1: 1) solution of 100g aquation 30min, use ultrasonic Treatment, promptly get the long circulating liposomes solution of 10-HCPT.The liposome branch is packed in the container, lyophilization, the lyophilizing long circulating liposome preparation of 10-hydroxycamptothecine.Logical nitrogen seals.
Embodiment 7.
With 10-hydroxycamptothecine 1g, phosphatidase 15 0g, cholesterol 15g, polyoxyethylene fatty acid ether (Brij-40) 5g is dissolved in chloroform: in the methanol (2: 1), rotary evaporation is removed organic solvent, vacuum drying, adding is dissolved with in the trehalose and sucrose water (1: 1) solution of 100g aquation 30min, use ultrasonic Treatment, promptly get the long circulating liposomes solution of 10-HCPT.The liposome branch is packed in the container, lyophilization, the lyophilizing long circulating liposome preparation of 10-hydroxycamptothecine.Logical nitrogen seals.Again after disperseing with normal saline, be suspended from the bag filter, be positioned in the commentaries on classics basket of digestion instrument.At 37 ℃, constant temperature vibration under the 60rmin-1 condition, different time points sampling 0.5ml, add 0.5ml release medium (the PBS buffer of pH7.4) simultaneously, sample carries out acidify through the 10ulHCL of 0.1M, and sample introduction 20ul carries out HPLC and measures, and calculates cumulative release percent (%).See Fig. 1.
Embodiment 8.
With 10-hydroxycamptothecine 1g, phosphatidase 15 0g, cholesterol 15g, polyoxyethylene hydrogenated Oleum Ricini (Cremophor) 5g is dissolved in chloroform: in the methanol (2: 1), rotary evaporation is removed organic solvent, vacuum drying, adding is dissolved with in the trehalose and sucrose water (1: 1) solution of 100g aquation 30min, use ultrasonic Treatment, promptly get the long circulating liposomes solution of 10-HCPT.The liposome branch is packed in the container, lyophilization, the lyophilizing long circulating liposome preparation of 10-hydroxycamptothecine.Logical nitrogen seals.Again after disperseing with normal saline, measure particle diameter, see Fig. 2 with Nicomp TM 380ZLS granularity and zeta potentiometer.
Embodiment 9.
HCPT's
125The I labelling adopts the Iodogen method.The HPCT that takes by weighing 3.3mg is dissolved in the 1mL methanol, therefrom gets 100 μ L solution and places the Iodogen pipe, adds 1～2mCi Na
125I is transferred to little centrifuge tube behind the slight oscillating reactions 5min, and the effective 300 μ L redistilled water washed twice of Iodogen are incorporated in the small test tube.
HPLC identifies and to show,
125The mark rate of I-HCPT is about 97%.
Get 24 of SD rats, be divided into 8 groups at random.Press 4.6875uCi/10g single dose tail vein injection HCPT aqueous solution for first group, second and third, four, five, six, seven groups press the 4.6875uCi/10g single dose respectively and inject the nanometer liposomes of modifying with Mrij-100, F68, Cremorphor RH 40, Mrij-40, F127, PEG-DSPE, get blood 0.5ml in the optical fundus respectively at 5min, 15min, 30min, 1h, 2h, 4h, 8h, 12h, 24h after the administration, gamma counter reads radiocounting.See Fig. 3.
Claims (8)
1. 10-hydroxycamptothecine long circulating liposome preparation, it is characterized in that with following weight proportion composition being that raw material is made lyophilized formulations: 10-hydroxycamptothecine 1-5 part, phosphatidase 11 0-100 part, lipid 10-100 part that PEG modifies, cholesterol 2-50 part, trehalose or sucrose 10-400 part.
2. according to the 10-hydroxycamptothecine long circulating liposome preparation of claim 1, it is characterized in that described phospholipid is lecithin, soybean phospholipid, hydrogenated soya phosphatide and any combining form thereof.
3. according to the 10-hydroxycamptothecine long circulating liposome preparation of claim 1, it is characterized in that described PEGization lipid is the hard ester acyl PHOSPHATIDYL ETHANOLAMINE of Polyethylene Glycol-two, the polyethylene glycol-caprolactone, polyethylene glycol-Acetic acid, hydroxy-, bimol. cyclic ester lactide, polyethylene glycol-lactic acid, poloxamer 188, polyoxyethylene fatty acid ester class, polyoxyethylene fatty acid ether and polyoxyethylene methyl Oleum Ricini ether one of them or any combining form.
4. the preparation method of the 10-hydroxycamptothecine long circulating liposome preparation of claim 1 is characterized in that following weight proportion composition is a raw material: 10-hydroxycamptothecine 1-5 part, phosphatidase 11 0-100 part, lipid 10-100 part that PEG modifies, cholesterol 2-50 part, trehalose or sucrose 10-400 part
10-hydroxycamptothecine, phospholipid, cholesterol are dissolved in dichloromethane according to the above ratio: in the methanol 2: 1, constant temperature removes and desolvates, add in the trehalose or aqueous sucrose solution that is dissolved with aforementioned proportion calculating, after the dissolving, ultrasonic or high-pressure homogenization is handled, divide in the container of packing into, lyophilization, the lyophilizing long circulating liposome preparation of 10-hydroxycamptothecine.
5. according to the method for claim 4, it is characterized in that described phospholipid is lecithin, soybean phospholipid or hydrogenated soya phosphatide.
6. according to the method for claim 4, it is characterized in that described PEGization lipid is the hard ester acyl PHOSPHATIDYL ETHANOLAMINE of Polyethylene Glycol-two, the polyethylene glycol-caprolactone, polyethylene glycol-Acetic acid, hydroxy-, bimol. cyclic ester lactide, polyethylene glycol-lactic acid, polyethylene glycol-cetyl cyanoacrylate, poloxamer 188, the polyoxyethylene fatty acid ester class, polyoxyethylene fatty acid ether and polyoxyethylene methyl Oleum Ricini ether one of them or any combining form.
7. according to the method for claim 4, it is characterized in that it is 40-60 ℃ that described constant temperature removes the temperature of desolvating.
8. according to the method for claim 4, wherein freezing back feeds nitrogen, helium or argon, rolls then and covers or seal.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100846473A CN1326525C (en) | 2004-11-26 | 2004-11-26 | 10-hydroxy camptothecin long cyclic liposome and its freeze aried preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100846473A CN1326525C (en) | 2004-11-26 | 2004-11-26 | 10-hydroxy camptothecin long cyclic liposome and its freeze aried preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1650864A true CN1650864A (en) | 2005-08-10 |
| CN1326525C CN1326525C (en) | 2007-07-18 |
Family
ID=34869244
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2004100846473A Expired - Fee Related CN1326525C (en) | 2004-11-26 | 2004-11-26 | 10-hydroxy camptothecin long cyclic liposome and its freeze aried preparation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1326525C (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100531720C (en) * | 2006-07-07 | 2009-08-26 | 中国科学院上海药物研究所 | A long-circulating nanoliposome carrier of hydroxycamptothecine and preparation method thereof |
| WO2011066684A1 (en) * | 2009-12-03 | 2011-06-09 | 江苏恒瑞医药股份有限公司 | Liposome of irinotecan or its hydrochloride and preparation method thereof |
| CN101744767B (en) * | 2008-12-05 | 2013-02-13 | 中国人民解放军军事医学科学院毒物药物研究所 | Thermal sensitive liposome preparation containing camptothecin antineoplastic agents |
| CN105777770A (en) * | 2014-12-26 | 2016-07-20 | 中国人民解放军第二军医大学 | Saturated long-chain fatty acid-modified 7-ethyl-10-hydroxycamptothecin compound and long-circulating liposome thereof |
| CN106109415A (en) * | 2016-07-26 | 2016-11-16 | 金华市人民医院 | A kind of load camptothecin antineoplastic agents liposome, preparation method and applications |
| CN115721610A (en) * | 2021-08-27 | 2023-03-03 | 沈阳药科大学 | 7-ethyl-10-hydroxycamptothecin compound liposome and preparation method and application thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL115099A (en) * | 1994-10-14 | 1999-04-11 | Upjohn Co | Lyophilizate of phospholipid complex of water insoluble camptothecins |
| CN1376468A (en) * | 2002-03-01 | 2002-10-30 | 深圳万乐药业有限公司 | Freeze dried hydroxy camptothecin powder for injection and its preparing process |
| CN1182849C (en) * | 2002-08-15 | 2005-01-05 | 黄石李时珍药业集团武汉李时珍药业有限公司 | Freeze dried hydroxycamptothecin powder injection and its preparing process |
| CN1236771C (en) * | 2003-04-14 | 2006-01-18 | 江苏省药物研究所 | Liposome of 10-hydroxycamptothecine, and its prepn. method |
-
2004
- 2004-11-26 CN CNB2004100846473A patent/CN1326525C/en not_active Expired - Fee Related
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100531720C (en) * | 2006-07-07 | 2009-08-26 | 中国科学院上海药物研究所 | A long-circulating nanoliposome carrier of hydroxycamptothecine and preparation method thereof |
| CN101744767B (en) * | 2008-12-05 | 2013-02-13 | 中国人民解放军军事医学科学院毒物药物研究所 | Thermal sensitive liposome preparation containing camptothecin antineoplastic agents |
| WO2011066684A1 (en) * | 2009-12-03 | 2011-06-09 | 江苏恒瑞医药股份有限公司 | Liposome of irinotecan or its hydrochloride and preparation method thereof |
| US10022365B2 (en) | 2009-12-03 | 2018-07-17 | Jiangsu Hengrui Medicine Co., Ltd. | Liposome of irinotecan or irinotecan hydrochloride and preparation method thereof |
| CN105777770A (en) * | 2014-12-26 | 2016-07-20 | 中国人民解放军第二军医大学 | Saturated long-chain fatty acid-modified 7-ethyl-10-hydroxycamptothecin compound and long-circulating liposome thereof |
| CN105777770B (en) * | 2014-12-26 | 2018-05-25 | 中国人民解放军第二军医大学 | A kind of the 7-Ethyl-10-hydroxycamptothecin compound and its long circulating liposome of saturated long chain fatty acid modification |
| CN106109415A (en) * | 2016-07-26 | 2016-11-16 | 金华市人民医院 | A kind of load camptothecin antineoplastic agents liposome, preparation method and applications |
| CN115721610A (en) * | 2021-08-27 | 2023-03-03 | 沈阳药科大学 | 7-ethyl-10-hydroxycamptothecin compound liposome and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1326525C (en) | 2007-07-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wang et al. | Cancer nanomedicines stabilized by π-π stacking between heterodimeric prodrugs enable exceptionally high drug loading capacity and safer delivery of drug combinations | |
| CN101485629B (en) | Drug delivery system and preparation method thereof | |
| CN1840193A (en) | Nanometer capsule of anthracene nucleus anticancer antibiotic with polyethylene glycol-phospholipid | |
| CN105456194A (en) | Magnolol liposome and derivative preparation and preparation method thereof | |
| CN108567742B (en) | SN38 lipid composition, preparation method and application thereof | |
| WO2021196659A1 (en) | Glycosyl polyether compound liposome, preparation method therefor and medicine thereof | |
| CN106109415B (en) | A kind of load camptothecin antineoplastic agents liposome, preparation method and applications | |
| CN112535676A (en) | Nano-structure lipid preparation for improving adriamycin tumor active targeting and kidney protection and preparation method thereof | |
| WO2008080369A1 (en) | Steady liposomal composition | |
| Shirsand et al. | Recent advances in niosomal drug delivery—A review | |
| CN102579317A (en) | Cantharidin vesicles and preparation thereof and preparation methods of cantharidin vesicles and preparation thereof | |
| CN110200921B (en) | Anti-inflammatory liposome with targeting effect and preparation and application thereof | |
| CN101028251A (en) | Camptothecine derivative phosphatide composite liposome nano-preparation and its making method | |
| CN114712514B (en) | Nanometer medicinal preparation for reducing blood fat locally and systemically, and its application | |
| CN105726494B (en) | Andrographolide nano suspension composition and its preparation method and application | |
| CN1931157A (en) | Polyene taxol liposome and its prepn process | |
| CN103622909A (en) | Cardiolipin-containing new liposome preparation, and its application in antitumor drugs | |
| CN107158395A (en) | A kind of Cabazitaxel phospholipid composite and its preparation method and application | |
| CN1326525C (en) | 10-hydroxy camptothecin long cyclic liposome and its freeze aried preparation | |
| CN1943566A (en) | Curcumin liposome and its method for preparing freeze-dried powder injection | |
| CN101322681B (en) | Method for preparing nano micelle formulation of anthracene nucleus antineoplastic antibiotic | |
| CN101062094B (en) | Total salvianolic acids long-cycle liposomes and the preparing method thereof | |
| CN1883455A (en) | A long-circulating nanoliposome carrier of hydroxycamptothecine and preparation method thereof | |
| Badri et al. | A review on niosomes as novel drug delivary system | |
| CN102188379B (en) | Preparation method of drug-carrying liposome |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070718 Termination date: 20101126 |